Events7th International Electronic Conference on Medicinal Chemistry
Published
This submission belongs to the session S3. General of the event 7th International Electronic Conference on Medicinal Chemistry
Published date
02 Nov, 2021
Academic Editor
author-avatarJean Jacques Vanden Eynde
Citation
Cristina Maccallini, Synthesis and biological evaluation of chalcone and stilbene based acetamidines as nitric oxide synthase inhibitors, in Proceedings of 7th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2021, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2021-11391
Share
Email
Facebook
Twitter
LinkedIn

Synthesis and biological evaluation of chalcone and stilbene based acetamidines as nitric oxide synthase inhibitors

image
1. Department of Pharmacy, University "G. d'Annunzio", Chieti-Pescara, via dei Vestini, 31, 66100 Chieti, Italy
Abstract

Nitric Oxide Synthases (NOS) are a family of oxidoreductases responsible for the biosynthesis of the free radical nitric oxide (NO). This is a very important signalling molecule involved in many different biological processes, both physiologic and pathologic.

In particular, the inhibition of the inducible NOS (iNOS) has been proposed as a targeted therapy in several diseases, including cancer, neurodegeneration and inflammatory bowel disease. In the past years our research group has disclosed different new potent and selective acetamidines as iNOS inhibitors, collecting evidence their usefulness as anticancer agents.

In the present work, starting from the observation that different chalcone-based compounds can modulate the iNOS expression levels, we have synthesised a set of acetamidin-chalcones and acetamidin-stilbenes and we evaluated them as inhibitors of the iNOS activity. Results obtained from these studies will be presented.

Keywords
Chalcone
inhibitors
nitric oxide synthases
synthesis
stilbene
Poster
2021.Electronic_Conference_on_Medicinal_Chemistry_pdf_MACCALLINI_C_final.pdf
Chemoprevention of ultraviolet B radiation-induced skin cancer with the mutant p53 reactivator SLMP53-2
Amphipathic malonates as potential antiviral agents